Maintenance of remission of ulcerative colitis: A comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 12, 1998, Pages 1207-1216

  Green, J R B ^a   Gibson, J A ^b   Kerr, G D ^c   Swarbrick, E T ^d   Lobo, A J ^e   Holdsworth, C D ^e   Crowe, J P ^f   Schofield, K J ^g   Taylor, M D ^g  

^a CITY GENERAL HOSPITAL   (United Kingdom)

^b Gastroenteroloy Unit

^c ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^d NEW CROSS HOSPITAL   (United Kingdom)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f Mater Misercordiae   (Ireland)

^g Astra Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FECES; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCUS; OCCULT BLOOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; ULCERATIVE COLITIS;

EID: 0031703575     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00427.x     Document Type: Article

References (24)

1. British Society of Gastroenterology. Guidelines in Gastroenterology 4: Inflammatory Bowel Disease. London: British Society of Gastroenterology. September 1996.
2. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 1997; 92: 204-11.
3. Misiewicz JJ, Lennard-Jones JE, Connell AM, Baron JH, Avery Jones F. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965; i: 185-8.
4. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitisation. Dig Dis Sci 1983; 28: 833-42.
5. Mansfield JC, Giaffer MH, Cann PA, Holdsworth CD, Thornton PC. Is high dose balsalazide (BSZ) better than sulphasalazine (SASP) in initial management of ulcerative colitis (UC)? Gut 1991; 32: A1217(Abstract).
6. Green JRB, Swan CHJ, Rowlinson AE, et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomised trial. Gastroenterology 1993; 104(Suppl. 4): A709(Abstract).
7. McIntyre PB, Lennard-Jones JE. Reversal with balsalazide of infertility caused by sulphasalazine. Br Med J 1984; 288: 1652-3.
8. Das KM, Eastwood MA, McManus JPA, Sircus W. Adverse reactions during salicylazosulphapyridine therapy and the relation with drug metabolism and acetylator phenotype. New Engl J Med 1973; 289: 491-5.
9. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; ii: 892-5.
10. Dew MJ, Hughes PJ, Lee MG, Evans BK, Rhodes J. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol 1982; 14: 405-8.
11. Dew MJ, Harries AD, Evans BK, Rhodes J. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take SASP. Lancet 1983; ii: 801.
12. Committee on Safety of Medicines. Current Problems. 1990: 30.
13. Stretch GL, Campbell BJ, Dwarakanath AD, et al. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. Aliment Pharmacol Ther 1996; 10: 941-7.
14. The Mesalazine Study Group. An oral preparation of mesalazine as a long-term maintenance therapy for ulcerative colitis - a randomised, placebo-controlled trial. Ann Intern Med 1996; 124: 204-11.
15. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 1383-9.
16. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-10.
17. Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988; 10: 306-10.
18. Green JRB. The treatment of ulcerative colitis with balsalazide sodium. Inflammopharmacology 1993; 2: 289-95.
19. McIntyre PB, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther 1988; 2: 237-43.
20. Green JRB, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalazine in acute ulcerative colitis (UC). Gastroenterology 1998; 114: 15-22.
21. Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-amino salicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992; 6: 51-9.
22. Green JRB, Swan CCJ, Rowlinson AE, et al. Short report: Comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992; 6: 647-52.
23. Hanauer SB. Topical and oral aminosalicylates. The management of inflammatory bowel disease: new medical surgical approaches. In: Peppercorn M, ed. New York: Marcel Dekker, 1990; 65-91.
24. Hanauer SB. Medical therapy of ulcerative colitis. Lancet 1993; 342: 412-17.